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Abstract 
Background and Purpose:  Patient centered outcomes are important.  We aimed to 
determine predictors of health-related quality of life (HRQoL) and develop utility-weighted 
modified Rankin scale (UW-mRS) scores in thrombolyzed acute ischemic stroke (AIS) 
patients from both arms of the Enhanced Control of Hypertension and Thrombolysis Stroke 
study (ENCHANTED). 
Methods:  ENCHANTED was an international quasi-factorial clinical trial of different doses 
of intravenous alteplase and intensities of blood pressure control in AIS patients, with 
outcomes on the European quality of life scale (EQ-5D) and mRS assessed at 90 days post-
randomization.  Logistic regression models were used to identify baseline predictors of poor 
HRQoL (≤mean EQ-5D utility scores).  Ordinary least squares regression derived UW-mRS 
scores. 
Results:  In 4016 AIS patients with complete EQ-5D and mRS data, independent predictors 
of poor HRQoL were older age (odds ratio 1.19, 95% confidence interval 1.12-1.27, per 10-
year increase), non-Asian ethnicity (1.91, 1.61-2.27), greater stroke severity on the National 
Institutes of Health Stroke Scale (NIHSS) (1.11, 1.09-1.12), diabetes mellitus (1.41, 1.18-
1.69), pre-morbid disability (mRS score 1 vs. 0; 1.62, 1.33-1.97), large vessel atheromatous 
etiology (1.32, 1.12-1.54) and proxy-respondent (2.35, 2.01-2.74).  Sensitivity analyzes 
indicate the ethnicity influence on HRQoL was driven by the high proportion of Chinese 
(62.9% of Asian) participants with better HRQoL compared to ‘non-Chinese’ or ‘other-
Asian’ groups.  Derived utility values across mRS scores 0 to 5 were 0.977, 0.885, 0.748, 
0.576, 0.194, and -0.174, respectively.  Correlations between mRS and EQ-5D scores were 
stronger in Asians. 
Conclusions:  HRQoL is worse after thrombolyzed AIS in the elderly, non-Asians, with 
greater initial severity, diabetes mellitus, pre-morbid disability, due to large vessel atheroma, 
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and proxy assessment.  The broader significance of better HRQoL in Asians is tempered by 
Chinese participants dominating analyzes.  From UW-mRS scores indicating the greatest 
steps in mRS scores are between 5 and 3, treatments to avoid major disability provide the 
greatest benefits for patients. 
Clinical Trial Registration-http://www.clinicaltrials.gov. Unique-identifier: NCT01422616 
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As stroke is the leading cause of adult disability and suffering,1,2 it is important to quantify 
the health and wellbeing of survivors that extend beyond functional status according to the 
modified Rankin scale (mRS), the most popular stroke outcome measure used in practice and 
research.  The mRS emphasizes the physical components of disability and inadequately 
captures the overall impact of stroke on one’s ‘healthy life’ or health-related quality of life 
(HRQoL).  A recent approach to address this deficiency is to produce utility-weighted mRS 
(UW-mRS) scores, which typically combine assessments on the 5-dimension European 
quality of life scale (EQ-5D) and mRS.  This allows the steps between mRS scores to move 
from fixed to variable intervals in an effort to directly reflect patient and societal valuation of 
disability states in a range from 0 (death) to 1 (perfect health).  We aimed to identify the 
clinical factors that determine ‘poor HRQoL’ and derive UW-mRS scores among all 
thrombolyzed patients with acute ischemic stroke (AIS) who participated in the international 
Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).   
Methods 
Data sharing 
Individual participant data used in these analyzes can be shared by request from any qualified 
investigator via the Research Office of The George Institute for Global Health, Australia.  
Study design 
ENCHANTED was an international, multi-center, 2 x 2 quasi-factorial, prospective, 
randomized open-label blinded-endpoint (PROBE) trial that assessed the effects of low-dose 
versus standard-dose intravenous alteplase, and intensive versus guideline-recommended 
blood pressure (BP) lowering, in thrombolysis-eligible patients with AIS, the details of which 
are outlined elsewhere.3-8  In brief, the ENCHANTED trial recruited an overall 4587 AIS 
patients, which included 3310 randomly assigned to low-dose (0.6mg/kg; 15% as bolus, 85% 
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as infusion over 1 hour) or standard-dose (0.9mg/kg; 10% as bolus, 90% as infusion over 1 
hour) intravenous alteplase; and 2227 treated with alteplase randomly assigned to intensive 
BP lowering (target systolic BP 130-140 mm Hg) or guideline recommended BP lowering 
(target systolic BP <180 mm Hg).  The study protocol was approved by the appropriate ethics 
committee at each participating center, and written informed consent was obtained from each 
patient or an appropriate surrogate.  The study is registered with Clinicaltrials.gov (number 
NCT01422616). 
Outcomes 
Key patient demographic and clinical characteristics were recorded at the time of enrolment.  
Their final stroke diagnoses by presumed etiology, including large vessel occlusion/stenosis 
due to atheroma, were reported by clinician investigators at Day 7 (or immediately before 
discharge, if earlier).  Neurological severity was measured using the National Institutes of 
Health Stroke Scale (NIHSS) at baseline, 24 hours, and Day 3 (or earlier on discharge from 
hospital).  Clinical outcomes were assessed by telephone or in-person by trained independent 
researchers at Day 90 post-randomization; the primary outcome being functional status on the 
mRS.  The secondary outcome was HRQoL on the EQ-5D-3L,9 which defines general health 
status across five dimensions (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) according to three levels of severity (1 = no problems, 2 = some/moderate 
problems, and 3 = severe problems).  Ratings on each subscale of the EQ-5D were synthesized 
into a single utility score using population-based preference weights obtained for the UK 
population.10-12  Utility scores range from -0.594 to 1, with scores of 1 and 0 representing 
perfect health and death, respectively; negative scores represent health states considered worse 
than death.10-12  For these analyzes, poor HRQoL was defined as scores of 2 or 3, defining 
problems reported within each dimension, or an overall health utility score ≤0.7 (rounded 
mean).  
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Statistical analysis 
Binary logistic regression was used to define associations between patient characteristics and 
poor HRQoL.  Sensitivity analyzes were performed to test associations of patient 
characteristics and poor HRQoL using different ethnicity analytic approaches, including non-
Chinese vs. Chinese, non-Asian vs. Chinese, non-Asian vs. other-Asian, and other-Asian vs. 
Chinese.  Association of NIHSS and EQ-5D utility scores (continuous variable) were 
assessed by linear regression.  Boxplots were used to demonstrate relationships of Day 90 
mRS scores and overall utility scores, while bar charts were used to describe relationships 
between mRS scores and individual dimensions on the EQ-5D.  EQ-5D utility score trends 
across all mRS levels, between Asian and non-Asian patients, and between Chinese and non-
Chinese, were tested using repeated measures analysis of variance.  Independent sample t-test 
was used to assess differences of EQ-5D utility score between different levels of the mRS, 
and at each level of the mRS score according to Asian vs. non-Asian, and Chinese vs. non-
Chinese.  Associations between mRS and EQ-5D utility scores were assessed using 
Spearman’s partial correlation analysis, adjusting for age and baseline NIHSS scores (≥14 vs. 
<14).  The proportion of variance in EQ-5D utility scores that were explained by mRS scores, 
were obtained from calculating the multiple correlation coefficient (r2) in regression models, 
adjusted for age and NIHSS scores (≥14 vs. <14).  Correlation coefficients for mRS and EQ-
5D utility scores were compared between Asians and non-Asians, and between Chinese and 
non-Chinese, using z test statistic with Fisher’s r to z transformation.13  Regression 
coefficients between Asians and non-Asians, and between Chinese and non-Chinese, were 
compared with an extensive t test.13  Associations between proxy-respondents and mRS were 
assessed by Spearman’s partial correlation analysis, and by logistic regression where mRS 
was considered as binary variable (0-1 vs. 2-5), adjusted for age, baseline NIHSS (≥14 vs. 
<14) and pre-stroke mRS (0 vs. 1).  Associations between proxy-respondents and baseline 
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NIHSS (≥14 vs. <14) were tested using logistic regression adjusted for age.  UW-mRS scores 
were derived from thrombolyzed participants in both the alteplase-dose and BP lowering 
intensity arms of the trial, using ordinary least squares (OLS) regression with mRS as a 
discrete ordinal explanatory dummy variable, and EQ-5D utility scores as a continuous 
response variable.14  Independent sample t-test was used to assess differences in mean UW-
mRS scores between the low-dose and standard-dose alteplase groups, and between intensive 
and guideline-recommended BP lowering groups.  Consistency in the results using UK utility 
weights were tested with Chinese utility weights.15, 16  Data are presented with odds ratios 
(OR) and 95% confidence intervals (CI), and a significance level was set at P <0.05.  All 
analyzes were undertaken using SAS enterprise (Version 7.1).   
Results 
Among all 4587 ENCHANTED AIS participants, there were 4016 (mean age 66.1; 37.6% 
female; 67.0% Asian [62.9% Chinese]) with available Day 90 mRS and EQ-5D utility scores.  
Differences between included and excluded participants are outlined in Supplemental Table I.   
The overall mean EQ-5D utility score of AIS patients was 0.72 (0.37).  Variables 
significantly associated with poor EQ-5D utility score (≤0.7) were older age (OR 1.19, 95% 
CI 1.12-1.27, per 10-year increase), non-Asian ethnicity (1.91, 1.61-2.27), greater NIHSS 
score (1.11, 1.09-1.12), diabetes mellitus (1.41, 1.18-1.69), pre-morbid disability (mRS score 
1 vs. 0; 1.62, 1.33-1.97), large vessel atheromatous etiology (1.32, 1.12-1.54) and use of 
proxy-respondent (2.35, 2.01-2.74) (Table 1).  In sensitivity analyzes using different ethnicity 
analytical approaches, there was general consistency for the same variables to be selected 
when comparing non-Chinese to Chinese, non-Asian to Chinese (except large vessel 
atheromatous etiology was no longer significant), and other-Asian to Chinese; except 
ethnicity was no longer significant when non-Asian was compared to other-Asian (without 
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Chinese) (Supplemental Tables II to V).  In particular, the general trend was for non-Asians 
to have poorer HRQoL compared to Asians (being predominantly Chinese).  
EQ-5D utility scores decreased by 0.02 per 1-point increase in NIHSS scores, after adjusting 
for age, sex, diabetes mellitus, and proxy-respondent.  Use of a proxy-respondent also had a 
significantly positive, albeit weak, correlation with mRS (r=0.29, P<0.0001; OR 1.16, 95% 
CI 1.09-1.22) after adjustment for age, baseline NIHSS and pre-stroke mRS.  High baseline 
NIHSS (≥14) was significantly associated with use of proxy-respondents (OR 2.52, 95% CI 
2.15-2.96, P<0.0001) for Day 90 outcome after adjustment for age.  Amongst the baseline 
variables that were associated with the different dimensions of EQ-5D, the general trend was 
for most, including age, previous smoke, atrial fibrillation, diabetes mellitus, pre-stroke 
disability, and stroke etiology, to be correlated with the physical components - poor 
function/activity domains, for non-Asian ethnicity as well as using anti-platelet agents at 
admission to be correlated with the non-physical components - poor pain/discomfort and 
emotion (anxiety/depression), and for baseline NIHSS and proxy assessment to be associated 
with poor HRQoL in all dimensions (Supplemental Table VI).   
Initial symptoms of unilateral weakness affecting the leg/foot and homonymous hemianopia, 
were significantly associated with poor EQ-5D utility score, after adjusting for age, sex, 
ethnicity, and stroke severity (Supplemental Table VII).  However, those associations that 
remained significant were paresis of the leg/foot in patients with poor (mRS 2-6) and good 
(mRS 0-1) functional outcomes, dysphasia in patients with poor functional outcome, and 
paresis of the arm/hand in those with good functional outcome (Supplemental Tables VIII 
and IX).  The general trend was for problems with the different EQ-5D dimensions to 
increase with progressive loss of function according to increasing mRS scores, with the 
largest step increases in problems to occur between scores 3 and 4, and 4 and 5 
(Supplemental Figure I). 
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Figure 1 shows a strong negative relationship between increasing mRS and EQ-5D utility 
scores (r=-0.83; P<0.0001), using UK utility weights.  The strength of this association was 
consistent using Chinese and UK utility weights for Chinese and non-Chinese participants, 
respectively (Supplemental Figure II).  Figure 2 shows a stronger correlation between these 
two outcome measures in Asians compared with non-Asians, and for significantly fewer 
problems (i.e. higher EQ-5D utility scores) to be recorded in Asians.  Similar results were 
seen when Chinese was compared with non-Chinese ethnicity (Supplemental Table X). 
UW-mRS scores across mRS scores 0 to 5 were: 0.977, 0.885, 0.748, 0.576, 0.194, and -
0.174, respectively (Supplemental Table XI).  The closest mRS levels were 0 and 1, separated 
by only 0.092, whereas the widest separation of levels was between 3 and 4 (0.382), and 4 
and 5 (0.368), respectively (all level differences, P <0.0001).  Sensitivity analyzes using 
Chinese utility weights for Chinese participants showed similar results (Supplemental Table 
XII).  Analysis of the separate arms of the ENCHANTED cohort using UW-mRS scores as 
the primary outcome measure showed no heterogeneity in the effects of low-dose (0.70±0.33) 
versus standard-dose (0.71±0.33) alteplase (P=0.418), and similarly no difference in the 
treatment effect of intensive BP lowering (0.74±0.32) versus guideline-recommended 
(0.72±0.32) BP lowering (P=0.379) in respective arms of the trial. 
Discussion 
These exploratory analyzes of the ENCHANTED trial outline the patterns and predictors of 
HRQoL following thrombolysis treatment for AIS.  Specifically, the independent predictors 
of poor HRQoL were older age, non-Asian ethnicity, more severe neurological impairment, 
diabetes mellitus, higher pre-stroke mRS (1 vs. 0), large vessel atheromatous etiology, and 
use of proxy-respondents.  Sensitivity analyzes showed the influence of ethnicity on HRQoL 
was driven by Chinese participants (62.9% of Asians) who had better HRQoL when 
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compared to either non-Chinese or other-Asian groups.  Although there was a strong 
correlation between Day 90 mRS and HRQoL utility scores, which was more strongly 
correlated in Asians than non-Asians, and in Chinese than non-Chinese participants, the 
combined UW-mRS scores were consistently unequally spaced across all six mRS levels.   
Our study confirms previous findings of age,17-19 female sex,17 diabetes mellitus,18, 20 
neurological severity,18, 19 having a negative influence on HRQoL, and for proxy-
respondents17, 21-23 to provide lower assessment of HRQoL than patients.  Moreover, the 
influence of diabetes mellitus appears to extend beyond physical functioning into memory 
and thinking.24  Although proxies are necessary to obtain EQ-5D scores in patients with 
severe disability, cognitive impairment or communication difficulty, it is clear that these data 
require adjusted analyses to account for their more pessimistic view of health states than 
patients.17, 21-23   
Ethnicity-specific differences in the perception of HRQoL have been noted by others.  For 
example, a large population-based study of national-level US data showed that Asians had 
higher HRQoL than Whites across a range of similar health and disease conditions,25 and was 
potentially explained by Asians having higher levels of perceived familial support than other 
groups.26  Another study of Chinese-American patients also suggests this ethnic group may 
be distinguished from others in having better HRQoL due to well preserved social/family 
ties,27 and strong relationships and support from friends.28  Thus, Asian ethnic groups appear 
to have high levels of collectivism, in which individuals have close binds, connections and 
obligations to social/family norms and duties,29 which may attenuate the adverse effects of 
illness, including stroke. 
Compared to other studies , the ENCHANTED cohort produced lower UW-mRS scores 
despite exhibiting similar trends in steps between mRS scores14  which may reflect 
differences between study populations and methods of deriving UW-mRS scores.  Our study 
12 
 
included a much larger multi-ethnic population specifically in thrombolysis-eligible and 
treated AIS patients20 than, for example, a UK study of 1283 patients with stroke or transient 
ischemic attack.14  Another study by Hong et al.,30 found even smaller HRQoL gaps between 
mRS scores 4 and 5, and 3 and 4,  than in our study.  However, the World Health 
Organization’s person-tradeoff procedure was used whereby stroke clinician derived 
disability weights were constrained to scores between 0 and 1, and unabled to account for 
scores worse than death.  
Strengths of our analyzes include the use of a large dataset derived from an international 
multicenter study where data collection was standardized and near complete according to a 
rigorous protocol.  Moreover, HRQoL measures were obtained from blinded assessors and 
sensitivity analyzes were undertaken according to Chinese and non-Chinese participants.  
Yet, as this was a selected clinical trial population with a restricted range of variables, there 
may be concerns over both the internal and external validity of the results.  Moreover, the use 
of UK reference scores on the EQ-5D may not accurately reflect utility scores of AIS patients 
in other populations, although our results were confirmed in sensitivity analysis using 
Chinese utility weights. 
In summary, the HRQoL of patients who survived thrombolyzed AIS was influenced by age, 
neurological severity, ethnicity, diabetes mellitus, pre-existing disability, large vessel 
atheromatous etiology and the use of proxy outcome assessment.  Although caution may be 
warranted regarding the broader generalizability of the influence of Asian ethnicity due to the 
high proportion of Chinese participants, there was consistency in analyzes indicating Asians 
had a better HRQoL compared to others.  In particular, there was a stronger correlation 
between mRS and EQ-5D scores in Asians (and Chinese) in the context of better overall 
HRQoL than non-Asians (and non-Chinese).  As UW-mRS values showed the largest steps 
between mRS scores 5 to 4, and 4 to 3, effective therapies targeting reduction in moderate-
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severe disability have the greatest potential to improve the health and wellbeing of those 
suffering AIS. 
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Table 1: Determinants of poor health-related quality of life in thrombolyzed patients with acute ischemic stroke 
 
Variables 
EQ-5D utility score* Univariable Multivariable 
>0.7 (2860) ≤0.7 (1156) OR P OR P 
Age (years) † 64.6 (12.6) 69.6 (12.0) 1.39 (1.31-1.47) <0.0001 1.19 (1.12-1.27)† <0.0001 
Female 1005/2860 (35.1) 503/1156 (43.5) 1.42 (1.24-1.63) <0.0001   
Non-Asian 838/2860 (29.3) 483/1156 (41.8) 1.73 (1.50-2.00) <0.0001 1.91 (1.61-2.27) <0.0001 
Clinical features       
   Systolic BP (mmHg) 153.6 (18.5) 154.2 (18.8) 1.00 (1.00-1.01) 0.324   
   NIHSS score 6 (4-10) 11 (6-16) 1.12 (1.11-1.14) <0.0001 1.11 (1.09-1.12) <0.0001 
Medical History       
   Hypertension 1799/2857 (63.0) 763/1155 (66.1) 1.15 (0.99-1.32) 0.065   
   Previous stroke 487/2860 (17.0) 220/1156 (19.0) 1.15 (0.96-1.37) 0.905   
   Coronary artery disease 347/2857(12.2) 184/1155 (15.9) 1.37 (1.13-1.66) 0.001   
   Atrial fibrillation 381/2855 (13.4) 252/1155 (21.8) 1.81 (1.52-2.16) <0.0001   
   Diabetes mellitus 520/2857 (18.2) 277/1155 (24.0) 1.42 (1.20-1.67) <0.0001 1.41 (1.18-1.69) 0.0002 
   Hypercholesterolemia 372/2857 (13.0) 234/1155 (20.3) 1.70 (1.42-2.03) <0.0001   
Pre-stroke mRS=1 342/2857 (12.0) 277/1153 (24.0) 2.33 (1.95-2.77) <0.0001 1.62 (1.33-1.97) <0.0001 
Medication at time of admission       
   Antihypertensive agents 1207/2857 (42.3) 583/1155 (50.5) 1.39 (1.22-1.60) <0.0001   
   Warfarin anticoagulation 46/2856 (1.6) 30/1153 (2.6) 1.63 (1.03-2.60) 0.039   
   Aspirin or other antiplatelet agents 524/2856 (18.4) 312/1153 (27.1) 1.65 (1.41-1.94) <0.0001   
   Glucose-lowering agents 322/2856 (11.3) 180/1153 (15.6) 1.46 (1.20-1.77) 0.0002   
   Lipid-lowering agents 451/2855 (15.8) 271/1153 (23.5) 1.64 (1.38-1.94) <0.0001   
Final diagnosis at time of hospital separation       
   Large vessel atheromatous etiology 1125/2853 (39.4) 498/1154 (43.2) 1.17 (1.02-1.34) 0.030 1.32 (1.12-1.54) 0.0008 
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Variables 
EQ-5D utility score* Univariable Multivariable 
>0.7 (2860) ≤0.7 (1156) OR P OR P 
   Small vessel disease 836/2853 (29.3) 189/1154 (16.4) 0.47 (0.40-0.56) <0.0001   
   Cardio-emboli 404/2853 (14.2) 252/1154 (21.8) 1.69 (1.42-2.02) <0.0001   
   Others 405/2853 (14.2) 195/1154 (16.9) 1.23 (1.02-1.48) 0.030   
Randomized to low-dose alteplase treatment 998/1994 (50.1) 451/869 (51.9) 0.93 (0.79-1.09) 0.363   
Randomized to intensive BP lowering treatment 732/1477 (49.6) 234/504 (46.4) 1.13 (0.93-1.39) 0.225   
Proxy-respondent 861/2859 (30.1) 641/1156 (55.5) 2.89 (2.51-3.33) <0.0001 2.35 (2.01-2.74) <0.0001 
Data are n (%), mean (SD), median (IQR), or odds ratio (95% confidence interval).  P values are based on Chi-square, T test,  
Wilcoxon signed-rank test, simple or multiple logistic regression. 
BP denotes blood pressure, EQ-5D EuroQol 5-dimensional questionnaire, mRS modified Rankin scale, NIHSS National Institutes of 
Health Stroke Scale, OR odds ratio 
*Good (above) and poor (below) mean scores on the EQ-5D 
†per 10-year increase 
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Figure legend 
Figure 1  Relation of mRS and EQ-5D utility scores 
Footnote: EQ-5D denotes the 5-dimension European quality of life scale and mRS modified 
Rankin scale.  R indicates Spearman’s correlation coefficient and R2 multiple 
regression coefficient 
 
Figure 2  Relation of mRS and EQ-5D utility score by Asian versus non-Asian, and by 
Chinese versus non-Chinese, ethnicity of participants 
Footnote: EQ-5D denotes the 5-dimension European quality of life scale and mRS modified 
Rankin scale.  P for trend relates to comparison of EQ-5D utility scores across all 
mRS scores, between Asian and non-Asian patients, and between Chinese and non-
Chinese, using repeated measures analysis of variance. 
* and ** indicate significantly different EQ-5D utility scores on each mRS score 
between Asian and non-Asian, and between Chinese and non-Chinese, patients. 
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Figure 1.  
 
0.97 (0.08)    0.89 (0.15)    0.75 (0.16)   0.58 (0.21)     0.19 (0.33)   -0.17 (0.21) Mean (SD)  
 1148 (28.6)   1075 (26.8)     637 (15.9)    521 (13.0)      411 (10.2)      224 (5.6) n (%) 
R*=-0.826 P<0.0001 
R2*=0.700 P<0.0001  
* adjusted for age and baseline NIHSS  
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Figure 2.  
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